Background: Mounting evidence suggests that recurrence of resected head and neck squamous cell carcinomas (HNSCCs) is due to the outgrowth of unrecognized residual tumor cells as well as to the premalignant and/or precursor-field epithelial cells. We studied the impact of processes triggered by HNSCC surgery in stimulating both residual tumor cells [demonstrated to overexpress epidermal growth factor receptor (EGFR)], and premalignant cells surrounding the resected lesion.
introduction
The epidermal growth factor receptor (EGFR) is overexpressed in most head and neck squamous cell carcinomas (HNSCCs). High levels of EGFR protein and of its ligand transforming growth factor-a (TGF-a) are predictors of reduced disease-free survival and reduced cause-specific survival [1] .
Advanced HNSCC tends to recur locoregionally after potentially curative surgical removal. Hence, postoperative adjuvant treatments such as radiation therapy or chemoradiotherapy are frequently required, at present delivered based on tumor stage and adverse pathological features. Tumor recurrence has been attributed traditionally to the outgrowth of a few unrecognized residual tumor cells, even in the presence of morphologically clear surgical margins. Recently, the role of premalignant cells surrounding the index tumor and sharing similar genetic alterations in the development of precursor fields has been suggested [2] [3] [4] [5] . In fact, morphologically normal mucosal cells in proximity of HNSC primary tumor frequently exhibit abnormally elevated expression of EGFR and TGF-a transcripts [6] , indicating a role for EGFR-related pathways in the carcinogenic process of the so-called 'condemned' mucosa.
Some evidence shows that processes triggered by surgery itself stimulate recurrence, particularly for tumors overexpressing EGFR family members [7] . Thus, EGF-like factors known to be released with surgery appear to be prime candidates as crucial molecules that could initiate and maintain tumor cell proliferation. In this study, we characterized the immunohistochemical, biochemical and gene EGFR profile of 23 HNSCC patients and we determined in vitro the role of EGFR family receptors in stimulating the proliferation of squamous carcinoma cell lines by wound healing fluids obtained from the same patients. We also examined the ability of several anti-EGFR family therapeutic agents to inhibit wound fluid cell line proliferation. Table 1 . The type of surgery is described in Table 2 . All tumors were formalin-fixed and paraffin-embedded for routine procedures; frozen tissue samples were obtained from some of the patients. Of the 23 patients, only one patient was found to have tumor cells at resection margins (R1 resection).
At an observation time of at least 36 months for all patients, 52% of the patients experienced a tumor relapse [9 (39%) at local regional site with or without metastases and 3 (13%) only at distant site]. 
EGFR analysis in tumor samples
immunohistochemistry. Formalin-fixed paraffin-embedded tumors were analyzed for EGFR protein expression using the EGFR-DAKO kit (DAKO, Glostrup, Denmark) and the results were scored as high, intermediate or low, as previously described [8] . In detail, EGFR-immunostained cells were quantitatively evaluated, as well as the staining intensity and scored as described in Table 3 . A final score obtained by combining the two score values was calculated.
immunoprecipitation/western blotting. Proteins were extracted from available frozen tissues [9] and were immunoprecipitated and blotted as described [10] . Briefly, EGFR was immunoprecipitated from 1 mg of protein lysate using 10 ll of anti-EGFR monoclonal antibody (MAb) (528:sc-120; Santa Cruz Biotechnology, Santa Cruz, CA), and probed with antiphosphotyrosine antibody (clone 4G10; Upstate, Lake Placid, NY) diluted 1:4000, followed by EGFR antibody (1005:sc-03l; Santa Cruz Biotechnology) diluted 1:200. A431 and CAL27 cell lysates were used as positive controls.
Fluorescence in situ hybridization. FISH analysis was carried out [8] and the samples were scored as FISH positive and negative as already described [11] .
characterization of EGFR status in A431 and CAL27 cell lines [8] of EGFR gene/chromosome 7 pattern revealed thatgene amplification coupled with chromosome 7 trisomy in A431 cells. CAL27 cells showed three EGFR gene copies, two of which related to chromosome 7 disomy and one represented by a potential insertion of the EGFR gene on a chromosome different from chromosome 7. DNA sequencing [12] of EGFR exons 18-21 revealed no activating mutations in the two cell lines, while a silent mutation, A2361G, was present affecting the residue Q787 in CAL27 cells.
results
EGFR expression/activation and gene status in tumors and peritumor mucosa tumor samples. To gain insight into EGFR expression/ activation in our collected HNSCC surgical specimens, EGFR protein was analyzed. IHC revealed high or intermediate levels of expression in all but two (91%) HNSCCs ( Figure 1A and Table 1 ). IP/WB to assess the status and expression of EGFR in samples with sufficient frozen material revealed two bands at 170 kDa, corresponding to the fully and partially glycosylated forms of the receptor, respectively, in all analyzed samples ( Figure 1B ), indicating the presence of activated EGFR. EGFR expression in the tumors was similar to or lower than that in positive control cell lines. FISH analysis was successfully carried out in 20 HNSCCs and revealed EGFR gene amplification or high polysomy (FISH positive) in seven (35%) samples (Table 1) .
tissues surrounding tumor. IHC analysis, aimed at determining whether EGFR expression involved also peritumor mucosa, indicated EGFR protein expression in morphologically normal epithelium, metaplastic and dysplastic surrounding areas (Figure 2A ). Biochemical analysis of frozen morphologically normal tissues adjacent to the tumor indicated significantly less EGFR expression than in tumor tissues but similar phosphorylation levels ( Figure 2B ).
FISH analysis of surgical specimens from four patients demonstrated an increased EGFR gene copy number (amplification cluster) in both the dysplastic area and the tumor in two patients ( Figure 2C ). As previously demonstrated in breast carcinoma [7] , the hypothesis that growth factors released during wound healing might trigger tumor proliferation in the surgical field was investigated using in vitro models mimicking the in vivo EGFR cytogenetic scenario detected in tumors and surrounding tissue. To this, two EGFR-overexpressing squamous carcinoma cell lines, A431 cell line carrying EGFR gene amplification and CAL27 cell line carrying three EGFR gene copies (see supplemental Materials and Methods, available at Annals of Oncology online) were employed. Both tumor cell lines A431 and CAL27 were induced to proliferate in response to each tested drainage fluid and drainage-induced proliferation compared with that driven by the same percentage of FCS was higher in CAL27 ( Figure 3A ). In addition, in both cell lines, wound fluids from 12 relapsed patients induced a significantly higher proliferation than the drainages from non-relapsed patients (P = 0.02 A431 and P = 0.03 CAL27) ( Figure 3B ).
Epidermal growth factor analysis in drainages fluids
Quantitation of epidermal growth factor (EGF) in patient drainages using enzyme-linked immunosorbent assay revealed an increase in the EGF levels in all drainage fluids compared with serum levels (240 pg/ml) and EGF amounts resulted similar in relapsed (at local regional site) compared with non relapsed patients (451.3 6 75.67 pg/ml versus 389.5 6 102.0 pg/ml) (unpaired t-test, P = 0.726 and Mann-Whitney test, P = 0.277).
drainage fluid proliferation capability and EGFR inhibitors
To verify the direct role of EGFR in the drainage-induced proliferation, cell lines were treated with wound fluids in the presence of neutralizing anti-EGF antibody, inhibitors of EGFR tyrosine kinase activity (gefitinib or lapatinib) or a humanized anti-EGFR MAb (cetuximab). Four days after drainage stimulation, Sulphorhodamine B colorimetric assay revealed a 70% and 95% decrease in drainage-induced growth of A431 cells incubated with anti-EGF antibody and gefitinib, respectively, while both lapatinib and cetuximab abolished the drainage-induced cell proliferation ( Figure 4 , left panel). Similar results were obtained in CAL27 cells (Figure 4 , right panel) with anti-EGF antibody, gefitinib and lapatinib, although gefitinib was more efficient than lapatinib. By contrast, cetuximab led only to 20% growth inhibition in CAL27 cells. No inhibition was observed in any cell line incubated with an EGFR-unrelated antibody (anti-CD20). Notably, all tested drugs at concentrations that inhibited the wound healing growth stimulation did not decrease the growth of tumor cells maintained in 1% FCS ( Figure S1 , available at Annals of Oncology online), indicating that the drugs' impact on the drainage-mediated proliferation was not due to direct toxicity on tumor cells. Cumulatively, these data suggest that EGFR plays a key role in drainagemediated cell proliferation of A431 cells, while in CAL27 cells, receptors of EGFR family other than EGFR might be also involved. To identify the other possible EGFR family receptors involved in drainage-dependent proliferation, expression of human epidermal growth factor receptor 2 (HER2) and v-erb-b2 erythroblastic leukemia viral oncogene homolog 3 (HER3), reported in squamous carcinoma cells [13] , was investigated. Indirect immunofluorescence revealed detectable and similar amounts of HER2 and HER3 in A431 and CAL27 cell lines ( Figure S2 , panel A, available at Annals of Oncology online). Moreover, in order to investigate a possible presence of EGFR-HER2 and EGFR-HER3 heterodimers, protein extracts were immunoprecipitated with EGFR antibody, blotted and subsequently incubated with EGFR, HER2, and HER3. As shown in Figure S2 panel B (available at Annals of Oncology online), a band in lane corresponding to HER2 was detectable in EGFR immunoprecipitated samples, thus indicating the presence of EGFR/HER2 heterodimers in both cell lines, especially in CAL27. By contrast, no evidence of EGFR/HER3 coimmunoprecipitation was observed (data not shown).
Furthermore, IP/WB analysis indicated that HNSCC drainage fluid stimulation, besides inducing a 6.5-fold increase of activation of overexpressed EGFR in both cell lines, led to increased HER2 and HER3 phosphorylation in CAL27 cells. Particularly, in CAL27 cells, HER2 and HER3 phosphorylation resulted to be 8-and 13-fold increased, respectively ( Figure  S2B , available at Annals of Oncology online); whereas in A431 cells no significant change in activation of these receptors was detected ( Figure S2 , panel C, available at Annals of Oncology online). As shown in Figure S2 , panel D (available at Annals of Oncology online), v-akt murine thymoma viral oncogene homolog (AKT) that lies downstream of the EGFR and HER2/3 activation, resulted more activated upon drainage stimulation for 30 min in both A431 and CAL27, while mitogen-activated protein kinase did not show evidence of phosphorylation increasing, suggesting that AKT is the main downstream signaling pathway activated by wound fluids.
Accordingly to these results, neutralizing antibodies against HER2 (trastuzumab) and HER3 inhibited 45% and 73% of the wound-induced CAL27 proliferation, respectively, as shown in titration experiments ( Figure 5, right panel) . On the contrary, original article Annals of Oncology no effect of these antibodies was observed in A431 cells ( Figure 5, left panel) . These data suggest that, although not overexpressed, HER3 and HER2 have a biologic role in wound healing-driven proliferation of CAL27 cells.
discussion
The present study demonstrates that drainage fluids derived from surgically resected HNSCCs contain EGF-like growth factors that induce proliferation of squamous carcinoma cell lines that appears to be triggered by EGFR expression and activation. Consistently, MAbs against EGFR and EGF and/or receptor tyrosine kinase inhibitors efficiently inhibit the drainage-induced proliferation of the cell lines. These findings have obvious clinical implications. Indeed, surgery-related release of EGF-like factors might per se lead to the promotion of EGFR-overexpressing cells, including residual tumor cells, premalignant and/or precursor-field epithelial cells that are not removed with surgery and/or not eliminated by postoperative irradiation. This is in keeping with the presence of EGFR upregulation/activation and EGFR gene amplification in the normal, metaplastic and dysplastic mucosa removed along with the tumor. In case of residual altered cells, these could be sensitive to EGFR inhibitors. Hence, after head and neck surgery, the presence of a potent EGF-and other ligandmediated proliferative milieu may confer a survival advantage on EGFR-overexpressing cells that may favor tumor reappearance. An indirect evidence of this phenomenon is the better outcome of HNSCC patients undergoing postoperative radiation therapy within 100 days from surgery as compared with cases delaying radiation. Moreover, the same waiting time for starting radiotherapy has been associated with an increased risk of local regional relapse in operated patients compared with those just receiving a curative radiation therapy [14] . These observations support the notion that residual tumor cells after surgery are highly proliferating, being more effectively controlled by timely delivered postoperative radiation when tumor outgrowth is still under a certain threshold [15] .
Relationship between drainage fluid proliferative capability and recurrence, with similar amounts of EGF in relapsing patients compared with uneventful ones, imply that also EGFlike factors (e.g. heparin binding-EGF and/or TGF-a), which are produced during the wound healing process [7] , contribute to drainage-mediated tumor cell proliferation. Moreover, cytokines associated with chronic inflammation and immune suppression, such as interleukin (IL)-8, IL-6, IL-1b, IL-10 and tumor necrosis factor-a, were detected in a significant amount in most draining fluids (data not shown).
Unfortunately our small series did not allow for correlate drainage fluid proliferative capability to the patient's outcome, separately from other clinical factors, including the type of postoperative treatment, well known to modulate the risk of recurrence.
Despite EGFR expression/activation, in both cell lines, a differential effect of the three EGFR inhibitors was observed under the same experimental EGF-like factor-mediated proliferative stimulus. In A431 cells, optimal inhibition of drainage-induced proliferation was achieved with MAbs, while CAL27 cell growth was more efficiently inhibited by the tyrosine kinase inhibitors than by cetuximab. The differential response to cetuximab of the two cell lines could be related to different explanations. Unlike CAL27 cells, A431 are vulva-derived cells expressing EGFR aberrant transcripts [16] that could show different affinity for MAbs against EGFR. Even the different EGFR gene copy number between the two lines can be called into question. However, no correlation between EGFR FISH status and tumor response to cetuximab in a recent study on recurrent and metastatic HNSCC patients was observed [17] . These data are in line with clinical findings reported in colorectal carcinoma [18, 19] . On the other hand, our experimental setting included cell lines reacting under potentially saturating EGF amounts, such as that discovered in our study, which cannot be anticipated in the treatment of patients with recurrent and metastatic disease. Considering that EGF and cetuximab have comparable binding affinities for the receptor [20] , the presence of EGFR gene amplification and the consequent high levels of the protein as in A431 cells might exceed the amounts of EGF-like factors available to completely saturate the increased receptor levels for efficient blocking by cetuximab. By contrast, EGF-like factors were able to reverse the growth inhibitory effect of cetuximab by a competitive mechanism in the presence of only three EGFR gene copies in CAL27 cells [21] . This competition may be bypassed by the use of receptor tyrosine kinase inhibitors such as lapatinib, which was equally effective in both cell lines. Indeed, it has been shown that saturating concentrations of EGF, as in wound drainages, are unable to revert the inhibitory effect of lapatinib [20] . In CAL27 cells, drainage fluids induced increasing of phosphorylation of both HER2 and HER3, possible EGFR dimerization partners; however, these molecules were not targetable by cetuximab. By contrast, no significant change in activation of these receptors was detected in A431 cells, suggesting that receptor activation in cells with EGFR gene amplification is driven mainly by homodimerization. Consistent with these observations, antibodies against HER2 and HER3 were effective only in CAL27 cells and their combined use had no effect on cell growth inhibition, suggesting a pivotal role for EGFR in family cross talk. Indeed, we demonstrated the presence of EGFR/HER2 heterodimers, particularly in CAL27 cells.
In this context, an early perioperative EGFR inhibiting treatment aimed at interfering with surgery-related EGFR family-mediated proliferative stimuli might be considered in addition to postsurgical maintenance treatments with these inhibitors. A similar approach has been adopted in breast cancer with the administration of preoperative chemotherapy and trastuzumab [7] .
In conclusion, in operated HNSCC patients, a postsurgical EGF-mediated environment that stimulates tumor survival could be successfully inhibited by EGFR inhibitors depending on the EGFR family status. Further research should focus on the safety of administering such drugs in the perioperative setting, coupled with a better understanding of the biological mechanisms underlying tumor sensitivity to different drugs. 
